Item 5.07  Submission of Matters to a Vote of Security Holders
Dicerna Pharmaceuticals, Inc. (the "Company") held its annual meeting of
stockholders (the "Annual Meeting") on June 3, 2021. The following proposals
were submitted to the stockholders at the Annual Meeting:
(i) To elect nine directors to the Company's board of directors, to serve until
the 2022 Annual Meeting and until his or her successor has been duly elected and
qualified, or until his or her earlier death, resignation or removal.
(ii) To ratify the appointment of Deloitte & Touche LLP as the Company's
independent registered public accounting firm for the fiscal year ending
December 31, 2021.
(iii) To approve, on a non-binding, advisory basis, the compensation of the
Company's named executive officers.
The proposals are described in detail in the Company's Proxy Statement filed
with the Securities and Exchange Commission on April 20, 2021.
The number of shares of common stock entitled to vote at the Annual Meeting was
76,614,989. The number of shares of common stock present or represented by valid
proxy at the Annual Meeting was 58,095,733. All matters submitted to a vote of
the Company's stockholders at the Annual Meeting were approved and all director
nominees were elected.
The number of votes cast for and against and the number of abstentions and
broker non-votes with respect to each matter voted upon are set forth below:
(a)Election of Directors.
                  Director Nominee                   For          Against         Abstain
         Douglas M. Fambrough, III, Ph.D.        51,486,490        28,788         22,909
         J. Kevin Buchi                          51,342,382       187,924          7,881
         Stephen Doberstein, Ph.D.               48,793,488      2,736,817         7,882
         Martin Freed, M.D.                      44,408,439      7,121,867         7,881
         Patrick M. Gray                         51,496,540        33,764          7,883
         Stephen J. Hoffman, M.D., Ph.D.         51,138,486       390,844          8,857
         Adam M. Koppel, M.D., Ph.D.             35,673,681      15,856,264        8,242
         Marc Kozin                              51,212,534       316,802          8,851
         Cynthia Smith                           48,782,289      2,747,460         8,438


There were no broker non-votes regarding the election of directors.
(b)Ratification of the appointment of Deloitte & Touche LLP as the Company's
independent registered public accounting firm for the fiscal year ending
December 31, 2021.
Stockholders ratified the appointment of Deloitte & Touche LLP as the Company's
independent registered public accounting firm for the fiscal year ending
December 31, 2021. The results of the voting included 57,745,711 votes for,
339,274 votes against and 10,748 votes abstained. There were no broker non-votes
regarding this proposal.
(c)Approval, on a non-binding, advisory basis, the compensation of the Company's
named executive officers.
Stockholders approved, on a non-binding, advisory basis, the compensation of the
Company's named executive officers. The results of the voting included
49,535,829 votes for, 1,969,888 votes against and 32,470 votes abstained. There
were no broker non-votes regarding this proposal.
Item 9.01  Financial Statements and Exhibits
(d) Exhibits
   Exhibit
     No.                                              Description
     104            Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses